Home / Information / Clinical Trials
Clinical Trials
On this page you will be able to see what clinical trials are, what they are trying to achieve, and how to get involved in them.
Clinical Trials in UK
Name
Summary
Action
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer
This study will compare the effectiveness of Alectinib with an Immunotherapy for ALK patients diagnosed at Stage III but unable to have surgery. The study will not report until 2033.
Immunotherapy or Targeted Therapy with or Without Stereotactic Radiosurgery for Patients with Brain Metastases from Non-small Cell Lung Cancer
The primary objective of the study is to assess the efficacy of the combination of standard systemic treatment plus radiotherapy to the brain versus standard systemic treatment alone. The study will report in 2026.
Navigational Bronchoscopy For Ablations of Tumours In The Lung
A trial at the Royal Brompton into the use of robotic-controled brochoscopy to ablate tumours in the lung.
Sacituzumab Tirumotecan Versus Chemotherapy in Previously Treated Advanced Non-small Cell Lung Cancer (NSCLC) With a Genomic Alteration
This study compares immunotherapy with chemotherapy for patients who have progressed on TKIs. Report not expected until 2030.
Neladalkib compared with Alectinib in Patients with Advanced ALK-positive NSCLC - the ALKAZAR Study.
A new Phase 3 trial will open in 2025 comparing neladalkib (formerly NVL-655) with Alectinib as a first line treatment for newly diagnosed patients.. The report is not expected until 2030.
UK Trials That Are No Longer Recruiting New Patients
Name
Summary of Contents
Action
Looking at Further Treatment After Initial Treatment for Advanced NSCLC (RAMON)
A study looking at further treatment after initial treatment for advanced non small cell lung cancer. Not ALK+ specific.
Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients (ALKALINE)
The purpose of this study is to identify which patient populations may benefit most from treatment with Lorlatinib, based on the alterations found in their genes. The study was due to complete in November 2024 but results have not yet been published.
Stereotactic Body Radiotherapy with Targeted Drug Treatment in Advanced NSCLC (HALT)
A trial of stereotactic body radiotherapy with targeted drug treatment in advanced non small lung cancer. Report expect Summer 2025.
NVL-655 in Patients with Advanced NSCLC and other Solid Tumours
A study of NVL-655 in patients who have progressed on other TKis and patients who have not received a prior TKI. (ALKOVE-1).
A report is expected before the end of 2025.
Although the study has closed, patients may still be able to access the drug under the Expanded Access Programe.
Studies of Interest
Name
Summary
Action
A Summary of Vaccine Studies In The UK
This document summarises information on vaccine Studies going on throughout the UK
ALINA: Efficacy & Safety of Adjuvant Alectinib vs Chemotherapy in Patients
Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ NSCLC
ALK Life Study - A Longitudinal Study
A Longitudinal survey for ALK+ Patients (now called the ALK Life Study)
CROWN Study Lorlatinib as 1st Line Treatment
Lorlatinib improved progression-free survival (PFS) and intracranial activity versus crizotinib in patients with previously untreated.
Funding Approved For a Vaccine In The UK
£1.7 million for the world's first vaccine to prevent lung cancer